Role of sex hormones in modulating breast and ovarian cancer associated pain
| Autor: | Josée Guindon, Henry L. Blanton, Melissa C. McHann |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.drug_class Analgesic Breast Neoplasms 030209 endocrinology & metabolism Biochemistry Article 03 medical and health sciences 0302 clinical medicine Endocrinology Breast cancer Internal medicine medicine Humans Molecular Targeted Therapy Molecular Biology Progesterone Ovarian Neoplasms Analgesics business.industry Incidence Incidence (epidemiology) Treatment options Cancer Estrogens Cancer Pain medicine.disease 030104 developmental biology Estrogen Female Ovarian cancer business Hormone |
| Zdroj: | Mol Cell Endocrinol |
| ISSN: | 0303-7207 |
| Popis: | According to the National Cancer Institute in 2020 there will be an estimated 21,750 new ovarian cancer cases and 276,480 new breast cancer cases. Both breast and ovarian cancer are hormone dependent cancers, meaning they cannot grow without the presence of hormones. The two most studied hormones in these two cancers are estrogen and progesterone, which are also involved in the modulation of pain. The incidence of pain in breast and ovarian cancer is very high. Research about mechanisms involved in modulation of pain by hormones are still being debated, as some studies find estrogen to be anti-nociceptive and others pro-nociceptive in pain studies. Moreover, analgesic treatments for breast and ovarian cancer-associated pain are limited and often ineffective. In this review, we will focus on estrogen and progesterone mechanisms of action in modulation of pain and cancer. We will also discuss new treatment options for these types of cancer and associated-pain. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect